Compare VTOL & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTOL | CSTL |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 940.8M |
| IPO Year | N/A | 2019 |
| Metric | VTOL | CSTL |
|---|---|---|
| Price | $44.45 | $32.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | N/A | ★ $46.67 |
| AVG Volume (30 Days) | 192.6K | ★ 403.7K |
| Earning Date | 02-27-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 148.42 | N/A |
| EPS | ★ 4.78 | N/A |
| Revenue | ★ $1,466,774,000.00 | $343,530,000.00 |
| Revenue This Year | $7.31 | $2.88 |
| Revenue Next Year | $9.48 | N/A |
| P/E Ratio | $9.23 | ★ N/A |
| Revenue Growth | 2.95 | ★ 10.15 |
| 52 Week Low | $25.11 | $14.59 |
| 52 Week High | $46.04 | $44.28 |
| Indicator | VTOL | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 57.43 | 33.24 |
| Support Level | $43.63 | $31.38 |
| Resistance Level | $46.04 | $33.10 |
| Average True Range (ATR) | 1.47 | 1.93 |
| MACD | -0.22 | -0.73 |
| Stochastic Oscillator | 32.76 | 14.92 |
Bristow Group Inc is the provider of vertical flight solutions. The group provides aviation services to a broad base of offshore energy companies and government entities. Its business comprises three reportable segments: Offshore Energy Services, Government Services, and Other Services. Its customers in Australia, Brazil, Canada, Chile, the Dutch Caribbean, the Falkland Islands, India, Ireland, the Kingdom of Saudi Arabia, Mexico, the Netherlands, Nigeria, Norway, Spain, Suriname, Trinidad, the UK, and the U.S. offshore energy customers use services to transport personnel to, from and between offshore energy installations.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.